Lonza 4D-Nucleofector LV Unit for non-viral primary T-cell transfection

Saturday, 10 September, 2016 | Supplied by: Capsugel Australia Pty Ltd

Lonza has announced its 4D-Nucleofector LV Unit, the latest addition to the 4D-Nucleofector System, which expands non-viral primary T-cell transfection to a closed, larger-scale format. Nucleofector Technology is said to improve on traditional electroporation methods to deliver enhanced transfection efficiencies while using less substrate and with only a moderate impact on cell viability. It is suitable for scientists working with hard-to-transfect cell types, like primary blood cells or stem cells.

The system was designed with the scientist in mind, so transfection protocols established on the existing smaller-scale unit can be smoothly transferred to the large-scale unit without the need for re-optimisation. The fully closed system is also suitable for use in a regulatory environment as it can be controlled by 21 CFR Part 11-compatible software. The addition of this larger-scale transfection format allows scientists to translate the results of their research applications into potential therapeutic applications.

Online: www.capsugel.com
Phone: 1300 657508
Related Products

Enzo Life Sciences SUPERKILLERTRAIL protein (soluble) (human), (recombinant)

Enzo Life Sciences' SUPERKILLERTRAIL (soluble) (human), (recombinant) is an enhanced ligand...

Diaclone ELISpot Kits

Diaclone's ELISpot Kits are highly specific immunoassays for the analysis of the production...

Bio-Rad Laboratories Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays

The assays allow scientists to measure neutralising antibodies quickly and efficiently against...

  • All content Copyright © 2022 Westwick-Farrow Pty Ltd